Skip to main content

Table 2 Detailed information of potential biomarkers from QDLS syndrome lung cancer patients compared to healthy volunteers

From: Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

No.

m/z

t(R)

Identification

Quasi-molecular ion

Formula

VIP

FC1

FC2

AUC

Trend

1

468.3080

2.1

LPC (14:0)

[M  +  H]+

C22H46NO7P

1.12

0.46**

1.24

0.86

↓

2

564.3279

2.8

LPC (18:2)

[M  +  HCOO]−

C26H50NO7P

1.41

0.42**

1.24

0.89

↓

3

720.5894

11.6

PC (O-16:0/16:0)

[M  +  H]+

C40H82NO7P

1.72

1.65*

1.09

0.83

↑

4

746.5686

10.7

PC (16:0/17:1)

[M  +  H]+

C41H80NO8P

1.46

2.59*

0.9

0.90

↑

5

768.5885

10.8

PC (O-16:0/20:4)

[M  +  H]+

C44H82NO7P

3.55

0.74*

1.2

0.76

↑

6

774.6002

11.5

PC (17:0/18:1)

[M  +  H]+

C43H84NO8P

2.06

1.88*

0.89

0.83

↑

7

782.5670

11

PC (18:1/16:0)

[M  +  Na]+

C42H82NO8P

1.54

1.70**

0.76

0.88

↑

8

794.5983

9.9

PC (P-18:0/20:4)

[M  +  H]+

C46H84NO7P

1.46

9.72**

0.13##

0.94

↑

9

808.5820

11.4

PC (18:2/18:0)

[M  +  Na]+

C44H84NO8P

1.84

2.01**

0.60##

1.00

↑

10

810.5980

12

PC (18:1/18:0)

[M  +  Na]+

C44H86NO8P

1.62

1.90**

0.67##

0.96

↑

11

822.6365

11.7

PC(P-20:0/20:4)

[M  +  H]+

C48H88NO7P

1.26

1.51*

0.89

0.79

↑

12

830.5652

10.3

PC (18:1/20:4)

[M  +  Na]+

C46H82NO8P

1.02

3.88**

0.24##

1.00

↑

13

832.5827

11.2

PC (20:4/18:0)

[M  +  Na]+

C46H84NO8P

1.43

3.06**

0.45##

1.00

↑

14

834.5987

11.6

PC (20:3/18:0)

[M  +  Na]+

C46H86NO8P

1.22

1.60**

0.55##

0.98

↑

15

716.5232

10.6

PE (16:0/18:2)

[M  +  H]+

C39H74NO8P

1.43

2.43*

0.79

0.80

↑

16

740.5218

10.5

PE (16:0/20:4)

[M  +  H]+

C41H74NO8P

1.15

2.05*

0.57#

0.89

↑

17

703.5732

10.1

SM (d18:1/16:0)

[M  +  H]+

C39H79N2O6P

8.01

0.74**

1.60##

0.91

↓

18

785.6531

12.3

SM (d18:2/22:0)

[M  +  H]+

C45H89N2O6P

4.8

0.59**

1.14

0.85

↓

19

787.6683

13.2

SM (d18:1/22:0)

[M  +  H]+

C45H91N2O6P

7.28

0.50**

1.27

0.89

↓

20

801.6831

13.9

SM (d18:1/23:0)

[M  +  H]+

C46H93N2O6P

3.56

0.52*

1.08

0.81

↓

21

803.6235

9.4

SM (d38:1)

[M  +  HCOO]−

C43H87N2O6P

1.5

0.22**

0.9

0.91

↓

22

815.7001

14.5

SM (d18:1/24:0)

[M  +  H]+

C47H95N2O6P

6.84

0.44*

1.2

0.85

↓

23

817.6405

9.8

SM (d39:1)

[M  +  HCOO]−

C44H89N2O6P

1.4

0.10**

2.12

0.88

↓

24

827.6993

13.5

SM (d18:2/25:0)

[M  +  H]+

C48H95N2O6P

1.46

2.52*

0.82

0.81

↑

25

833.6502

12.2

SM (d18:2/24:1)

[M  +  Na]+

C47H91N2O6P

1.7

2.49**

0.69##

1.00

↑

26

843.6582

9.9

SM (d41:2)

[M  +  HCOO]−

C46H91N2O6P

1.38

0.22**

1.1

0.96

↓

27

591.4952

13.1

DG (16:0/18:3)

[M  +  H]+

C37H66O5

1.71

1.84**

0.59##

0.98

↑

28

607.5652

15.5

DG (18:0/18:0)

[M  +  H–H2O]+

C39H76O5

3.04

2.00**

0.46##

0.99

↑

29

619.5262

14.3

DG (16:0/18:0)

[M  +  Na]+

C37H72O5

2.93

2.16**

0.61##

1.00

↑

30

643.5260

13.3

DG (18:1/18:1)

[M  +  Na]+

C39H72O5

1.24

6.03**

0.56

0.95

↑

31

834.7539

18.4

TG (15:0/16:0/18:2)

[M  +  NH4]+

C52H96O6

1.17

2.22*

0.66

0.83

↑

32

836.7693

18.6

TG (15:0/16:0/18:1)

[M  +  NH4]+

C52H98O6

1.28

4.15**

0.54

0.94

↑

33

853.7252

18.5

TG (16:0/18:2/18:3)

[M  +  H]+

C55H96O6

1.19

2.31**

0.52#

0.93

↑

34

855.7433

18.3

TG (16:0/18:1/18:3)

[M  +  H]+

C55H98O6

1.79

2.51**

0.54#

0.96

↑

35

857.7583

18.5

TG (16:0/18:1/18:2)

[M  +  H]+

C55H100O6

1.06

3.98**

0.54#

1.00

↑

36

862.7854

18.6

TG (16:0/17:1/18:1)

[M  +  NH4]+

C54H100O6

1.93

2.98*

0.88

0.83

↑

37

864.8012

18.9

TG (16:0/17:0/18:1)

[M  +  NH4]+

C54H102O6

1.83

3.37*

0.82

0.79

↑

38

881.7579

18.7

TG (16:0/18:1/20:4)

[M  +  H]+

C57H100O6

2.31

2.38**

0.61##

1.00

↑

39

883.7702

19

TG (16:0/18:1/20:3)

[M  +  H]+

C57H102O6

1.7

4.39**

0.50#

0.93

↑

40

888.8010

18.6

TG (17:0/18:1/18:2)

[M  +  NH4]+

C56H102O6

2.04

2.75*

0.77

0.81

↑

41

892.7380

17.7

TG (14:0/18:2/22:6)

[M  +  NH4]+

C57H94O6

1.23

0.33*

0.68

0.19

↓

42

892.8325

19.1

TG (17:0/18:0/18:1)

[M  +  NH4]+

C56H106O6

1.27

14.99*

0.39

0.93

↑

43

894.7542

17.7

TG (18:2/18:2/18:3)

[M  +  NH4]+

C57H96O6

4.35

0.37*

0.99

0.13

↓

44

907.7727

18.8

TG (18:1/18:1/20:4)

[M  +  H]+

C59H102O6

1.52

2.42**

0.56##

0.96

↑

45

909.7853

19

TG (18:0/18:1/18:1)

[M  +  Na]+

C57H106O6

1.39

3.89**

0.62

0.95

↑

46

918.7540

17.6

TG (18:2/18:2/20:5)

[M  +  NH4]+

C59H96O6

1.54

0.37*

0.88

0.16

↓

47

928.8294

18.8

TG (18:0/18:1/20:3)

[M  +  NH4]+

C59H106O6

1.61

1.75*

0.73

0.78

↑

48

932.8636

19.2

TG (16:0/18:1/22:1)

[M  +  NH4]+

C59H110O6

1.09

2.12*

0.52

0.81

↑

49

952.8320

18.7

TG (18:1/18:1/22:4)

[M  +  NH4]+

C61H106O6

1.12

3.54**

0.46

0.90

↑

50

630.6178

14.6

Cer (d18:1/24:1)

[M  +  H–H2O]+

C42H81NO3

1.03

2.29*

0.78

0.74

↑

51

369.3521

10.3

Cholesterol

[M  +  H–H2O]+

C27H46O

1.21

2.18*

0.45##

0.99

↑

  1. QDLS for whom suffered Qi deficiency of lung-spleen; FC1 the ion intensity ratio of potential biomarkers from QDLS/healthy volunteers by using the developed UHPLC-Q-TOF/MS method; FC2 the ion intensity ratio of potential biomarkers from QDLS-Treatment/QDLS by using the developed UHPLC-Q-TOF/MS method, QDLS-Treatment for whom suffered Qi deficiency of lung-spleen and treated by Kangai Injection
  2. *p  < 0.05 and  **p  < 0.01, QDLS vs. H group
  3. #p  < 0.05 and ##p  < 0.01,  QDLS-Treatment vs. QDLS group
Back to article page

Chinese Medicine

ISSN: 1749-8546

Contact us